Does protease-antiprotease imbalance explain Chronic obstructive pulmonary disease?

Annals of the American Thoracic Society

Volumn 13, Issue , 2016, Pages S130-S137

  Lomas, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha 1 antitrypsin deficiency; Genetics; Polymers

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RNA; PEPTIDE HYDROLASE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DISEASE PREDISPOSITION; EMPHYSEMA; ENVIRONMENTAL FACTOR; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HUMAN; PATHOGENESIS; POLYMERIZATION; GENETICS; LUNG; LUNG EMPHYSEMA; METABOLISM; PATHOPHYSIOLOGY;

HUMANS; LUNG; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA;

EID: 84989234503     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201504-196KV     Document Type: Conference Paper

References (81)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
2. Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health 1965;11:50-58.
3. 1-antitrypsin deficiency. Acta Med Scand Suppl 1965;432:1-85.
4. Marciniak SJ, Lomas DA. What can naturally occurring mutations tell us about the pathogenesis of COPD? Thorax 2009;64:359-364.
5. Murray CJL, Lopez AD. Global burden of disease and injury series, Vol. II: Global health statistics: a compendium of incidence, prevalence, and mortality estimates for over 200 conditions. Cambridge, MA: Harvard School of Public Medicine; 1999.
6. Peto R, Chen Z-M, Boreham J. Tobacco-the growing epidemic. Nat Med 1999;5:15-17.
7. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648.
8. Mason RJ, Buist AS, Fisher EB, Merchant JA, Samet JM, Welsh CH; American Thoracic Society. Cigarette smoking and health. Am Rev Respir Dis 1985;132:1133-1136.
9. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195-205.
10. Dockery DW, Speizer FE, Ferris BG Jr, Ware JH, Louis TA, Spiro A III. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis 1988;137:286-292.
11. Peat JK, Woolcock AJ, Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of nonsmokers and smokers in Busselton, Western Australia. Thorax 1990;45:32-37.
12. Barker DJP, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991;303:671-675.
13. Wang X, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG Jr, Dockery DW. A longitudinal study of the effects of parental smoking on pulmonary function in children 6-18 years. Am J Respir Crit Care Med 1994;149:1420-1425.
14. Colley JR, Douglas JW, Reid DD. Respiratory disease in young adults: influence of early childhood lower respiratory tract illness, social class, air pollution, and smoking. BMJ 1973;3:195-198.
15. Kauffmann F, Drouet D, Lellouch J, Brille D. Twelve years spirometric changes among Paris area workers. Int J Epidemiol 1979;8:201-212.
16. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-1861.
17. Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, Turino GM. Atopy, asthma, and emphysema in patients with severe a-1-antitrypsin deficiency. Am J Respir Crit Care Med 1997;156:68-74.
18. Logan WPD. Mortality in the London fog incident, 1952. Lancet 1953;1:336-338.
19. Ulvestad B, Bakke B, Melbostad E, Fuglerud P, Kongerud J, Lund MB. Increased risk of obstructive pulmonary disease in tunnel workers. Thorax 2000;55:277-282.
20. Sridhar MK. Nutrition and lung health. Proc Nutr Soc 1999;58:303-308.
21. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al.; ECLIPSE Investigators. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-873.
22. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
23. Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Should we view COPD differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014;189:1022-1030.
24. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, et al.; ECLIPSE Study Investigators. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014;69:666-672.
25. Agustí A, Calverley PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
26. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mü llerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
27. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, et al.; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-1192.
28. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Crim C, Duvoix A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE Study. Lancet Respir Med 2013;1:129-136.
29. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, et al.; ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-1072.
30. Patel BD, Coxson HO, Pillai SG, Agustí AG, Calverley PM, Donner CF, Make BJ, Müller NL, Rennard SI, Vestbo J, et al.; International COPD Genetics Network. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:500-505.
31. 1-antitrypsin accumulation in the liver. Nature 1992;357:605-607.
32. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alAT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology 2005;41:160-167.
33. 1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002;136:270-279.
34. 1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004;59:843-849.
35. Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001;289:116-119.
36. Zhou M, Huang SG, Wan HY, Li B, Deng WW, Li M. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004;117:1481-1484.
37. Tesfaigzi Y, Myers OB, Stidley CA, Schwalm K, Picchi M, Crowell RE, Gilliland FD, Belinsky SA. Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. Int J Chron Obstruct Pulmon Dis 2006;1:267-278.
38. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11:569-576.
39. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, Stidley C, Melé n E, Sö derhäll C, Hallberg J, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361:2599-2608.
40. Haq I, Lowrey GE, Kalsheker N, Johnson SR. Matrix metalloproteinase-12 (MMP-12) SNP affects MMP activity, lung macrophage infiltration and protects against emphysema in COPD. Thorax 2011;66:970-976.
41. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al.; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5:e1000421.
42. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK; ECLIPSE and ICGN Investigators. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:1498-1505.
43. Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CHRNA3 genotype, nicotine dependence, lung function and disease in the general population. Eur Respir J 2012;40:1538-1544.
44. Hardin M, Zielinski J, Wan ES, Hersh CP, Castaldi PJ, Schwinder E, Hawrylkiewicz I, Sliwinski P, Cho MH, Silverman EK. CHRNA3/5, IREB2, and ADCY2 are associated with severe chronic obstructive pulmonary disease in Poland. Am J Respir Cell Mol Biol 2012;47:203-208.
45. Wilk JB, Shrine NR, Loehr LR, Zhao JH, Manichaikul A, Lopez LM, Smith AV, Heckbert SR, Smolonska J, Tang W, et al. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med 2012;186:622-632.
46. Siedlinski M, Tingley D, Lipman PJ, Cho MH, Litonjua AA, Sparrow D, Bakke P, Gulsvik A, Lomas DA, Anderson W, et al.; COPDGene and ECLIPSE Investigators. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 2013;132:431-441.
47. Lambrechts D, Buysschaert I, Zanen P, Coolen J, Lays N, Cuppens H, Groen HJ, Dewever W, van Klaveren RJ, Verschakelen J, et al. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 2010;181:486-493.
48. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A, Bueno R, Pillai SG, Lomas DA, Sparrow D, et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009;85:493-502.
49. Chappell SL, Daly L, Lotya J, Alsaegh A, Guetta-Baranes T, Roca J, Rabinovich R, Morgan K, Millar AB, Donnelly SC, et al. The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet 2011;12:24.
50. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010;42:200-202.
51. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, Myers RH, Borecki IB, Silverman EK, Weiss ST, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet 2009;5:e1000429.
52. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, et al.; Wellcome Trust Case Control Consortium; NSHD Respiratory Study Team. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010;42:36-44.
53. Van Durme YM, Eijgelsheim M, Joos GF, Hofman A, Uitterlinden AG, Brusselle GG, Stricker BH. Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. Eur Respir J 2010;36:89-95.
54. Zhou X, Baron RM, Hardin M, Cho MH, Zielinski J, Hawrylkiewicz I, Sliwinski P, Hersh CP, Mancini JD, Lu K, et al. Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum Mol Genet 2012;21:1325-1335.
55. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, et al.; ICGN Investigators; ECLIPSE Investigators; COPDGene Investigators. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012;21:947-957.
56. Wan ES, Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Won S, Lange C, Pillai SG, Anderson WH, et al.; Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate End-Points (ECLIPSE); Norway-Bergen Cohort; National Emphysema Treatment Trial; COPDGene Investigators. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011;45:304-310.
57. Kong X, Cho MH, Anderson W, Coxson HO, Muller N, Washko G, Hoffman EA, Bakke P, Gulsvik A, Lomas DA, et al.; ECLIPSE Study NETT Investigators. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 2011;183:43-49.
58. Bamforth FJ, Kalsheker NA. Alpha 1 antitrypsin deficiency due to Pi null: clinical presentation and evidence for molecular heterogeneity. J Med Genet 1988;25:83-87.
59. Lomas DA, Stone SR, Llewellyn-Jones C, Keogan M-T, Wang ZM, Rubin H, Carrell RW, Stockley RA. The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin. J Biol Chem 1995;270:23437-23443.
60. 1-Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120:4236-4250.
61. 1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci USA 2013;110:15007-15012.
62. 1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998;18:670-674.
63. Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, McElvaney NGZ. Z α1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004;125:1952-1957.
64. 1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166:377-386.
65. 1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol 2011;45:261-269.
66. 1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002;26:723-730.
67. 1-antitrypsin deficiency-related panniculitis: demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology 2009;218:370-375.
68. 1antitrypsin and its polymers. Ann Rheum Dis 2011;70:1851-1856.
69. Gooptu B, Lomas DA. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 2008;205:1529-1534.
70. 1-antitrypsin deficiency. Eur Respir J 2014;43:1501-1504.
71. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011;5:391-405.
72. 1-antitrypsin-related cirrhosis. J Biol Chem 2002;277:6771-6774.
73. Gooptu B, Miranda E, Nobeli I, Mallya M, Purkiss A, Brown SC, Summers C, Phillips RL, Lomas DA, Barrett TE. Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design. J Mol Biol 2009;387:857-868.
74. 1-antitrypsin to prevent conformational disease. J Biol Chem 2003;278:33060-33066.
75. 1-antitrypsin conformers. PLoS One 2012;7:e36612.
76. 1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 2007;50:5357-5363.
77. 1-antitrypsin deficiency. Hepatology 2010;52:1078-1088.
78. 1-antitrypsin polymerisation using a novel monoclonal antibody. Int J Biochem Cell Biol 2015;58:81-91.
79. Irving JA, Miranda E, Haq I, Perez J, Kotov VR, Faull SV, Motamedi-Shad N, Lomas DA. An antibody raised against a pathogenic serpin variant induces mutant-like behaviour in the wild-type protein. Biochem J 2015;468:99-108.
80. 1-antitrypsin while allowing its antiproteinase activity. FASEB J 2015;29:2667-2678.
81. Guo S, Booten SL, Aghajan M, Hung G, Zhao C, Blomenkamp K, Gattis D, Watt A, Freier SM, Teckman JH, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest 2014;124:251-261.